EU Pilots New 'Stepwise' Approach To Pediatric Investigation Plans
Executive Summary
New EU guidance has been published to help the European Medicines Agency and drug developers agree on the conduct of pediatric investigation plans (PIPs) when crucial information is not yet available.
You may also be interested in...
EMA’s Pediatrics Group To Focus On ‘Stepwise’ PIPs & Using RWE In 2024
The European Medicines Agency has drawn up an action plan for its pediatrics committee that will see existing initiatives, such as the introduction of a ‘stepwise’ approach to pediatric investigation plans, further developed this year.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.